LivaNova receives increased CMS reimbursement for VNS Therapy

LivaNova (LIVN) announced that the U.S. Centers for Medicare & Medicaid Services, or CMS, assigned VNS Therapy for drug-resistant epilepsy to new technology ambulatory payment classification 1580 for new patient implants under the 2026 Medicare Hospital Outpatient Prospective Payment System. CMS also moved VNS Therapy end-of-service procedures from level 4 into the level 5 ambulatory payment classification. Effective Jan. 1, 2026, provider reimbursement for VNS Therapy procedures under Medicare will increase, with hospital outpatient payments rising by approximately 48% for new patient implants and 47% for end-of-service procedures vs. 2025 rates.